Clayton Rabideau
Clayton is the founder of Syntensor, a startup that develops frontier models for drug development and human genetics with a particular focus on predicting the underlying drivers of clinical trial outcomes and trait prediction from human genomes.
â€
Syntensor Incorporated
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
-
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495